By Hendra Lukman 
A pioneering gene therapy developed by scientists at University College London (UCL) and Great Ormond Street Hospital (GOSH) is demonstrating significant promise for pediatric and adult patients battling T-cell acute lymphoblastic leukemia (T-ALL), a rare and aggressive blood cancer. This innovative treatment, known as BE-CAR7, employs genome-edited immune cells to precisely target and eliminate the disease, offering a vital new avenue for individuals with limited conventional treatment options.
The Dawn of Precision Medicine: BE-CAR7 Gene Therapy
BE-CAR7 represents a significant advancement in the field of gene therapy, specifically designed to combat forms of T-cell leukemia that have historically proven resistant to established treatments. Unlike traditional gene editing methods that involve cutting DNA, this next-generation approach utilizes base-editing technology, an advanced form of CRISPR gene editing. Base-editing allows for the precise alteration of individual DNA "letters" within living cells, minimizing the risk of unintended genetic damage and enhancing the safety profile of the therapy.
This sophisticated technique reprograms a patient’s own immune cells, specifically T-cells, equipping them with a chimeric antigen receptor (CAR). This engineered receptor acts like a highly specific homing device, enabling the T-cells to identify and destroy cancer cells that display particular markers, or "flags," on their surface. The development of CAR T-cell therapies for T-cell leukemias presented a unique challenge: ensuring that the engineered cells could effectively eliminate cancerous T-cells without also attacking healthy T-cells, a crucial distinction for maintaining immune system integrity.
A Landmark Moment: The First Patient and Expanding Trials
The groundbreaking potential of BE-CAR7 was first realized in 2022 when researchers at GOSH and UCL administered the therapy to Alyssa, a 13-year-old girl from Leicester. This marked a historic moment as the first instance worldwide of a base-edited therapy being used in a patient. Alyssa’s case served as a crucial proof-of-concept, paving the way for further clinical investigation.
Since Alyssa’s treatment, the BE-CAR7 therapy has been administered to an additional eight children and two adults across GOSH and King’s College Hospital (KCH). The ongoing clinical trials are meticulously gathering data to assess the efficacy and safety of this novel approach.
Promising Clinical Trial Outcomes: Remission Rates and Expert Insights
Early findings from the clinical trial have been published in the prestigious New England Journal of Medicine and presented at the 67th American Society of Hematology Annual Meeting, underscoring the significance of the research. While specific remission rate percentages for the entire cohort were not detailed in the initial reports, the qualitative outcomes and expert commentary highlight substantial success.
Professor Waseem Qasim, who spearheaded the research as Professor of Cell and Gene Therapy at UCL and honorary consultant immunologist at GOSH, expressed optimism about the expanded trial results. "We previously showed promising results using precision genome editing for children with aggressive blood cancer, and this larger number of patients confirms the impact of this type of treatment," Professor Qasim stated. "We’ve shown that universal or ‘off the shelf’ base-edited CAR T-cells can seek and destroy very resistant cases of CD7+ leukemia." He emphasized the collaborative effort involved, acknowledging the dedication of numerous teams across the hospital and university.
Professor Qasim also offered a poignant perspective on the intensity of the treatment and the emotional toll on patients and their families. "Many teams were involved across the hospital and university, and everyone is delighted for patients clearing their disease, but at the same time, deeply mindful that outcomes were not as hoped for some children. These are intense and difficult treatments—patients and families have been generous in recognizing the importance of learning as much as possible from each experience."
Dr. Rob Chiesa, a study investigator and bone marrow transplant consultant at GOSH, echoed these sentiments, emphasizing the unmet need for effective treatments for a subset of T-cell leukemia patients. "Although most children with T-cell leukemia will respond well to standard treatments, around 20% may not," Dr. Chiesa explained. "It’s these patients who desperately need better options, and this research provides hope for a better prognosis for everyone diagnosed with this rare but aggressive form of blood cancer." He further highlighted the comprehensive care required, stating, "Seeing Alyssa go from strength-to-strength is incredible and a testament to her tenacity and the dedication of an array of small army of people at GOSH. Team working between bone marrow transplant, hematology, ward staff, teachers, play workers, physiotherapists, lab and research teams, among others, is essential for supporting our patients."
Dr. Deborah Yallop, a consultant hematologist at KCH, provided a concise yet powerful summary of the therapy’s impact: "We’ve seen impressive responses in clearing leukemia that seemed incurable—it’s a very powerful approach."
The Science Behind BE-CAR7: Universal CAR T-Cells and Manufacturing
The development of "universal" CAR T-cells is a key innovation of the BE-CAR7 therapy. This approach, enabled by base-editing, allows for the creation of banked stores of T-cells that can be readily administered to different patients, eliminating the need for lengthy cell manufacturing processes tailored to each individual. These universal CAR T-cells are derived from the white blood cells of healthy donors and are genetically modified in a highly controlled clean room environment at GOSH.
The manufacturing process involves sophisticated techniques, including the use of custom RNA, mRNA, and a lentiviral vector within an automated system that the research team has previously refined. The base-editing technology employed does not cut DNA, thereby significantly reducing the risk of chromosomal damage compared to older gene-editing methods. The specific edits target genes that are crucial for preventing the engineered T-cells from attacking healthy T-cells, a critical safety mechanism.
From Eradication to Restoration: The Treatment Pathway
Once administered, the BE-CAR7 T-cells swiftly locate and neutralize T-cells throughout the body, including the cancerous leukemia cells. If the leukemia is successfully eradicated within the initial month of treatment, patients then undergo a bone marrow transplant. This crucial step aims to restore a healthy and functioning immune system over the subsequent months, a process that requires careful monitoring and supportive care.
A Chronicle of Hope: Alyssa’s Journey and Future Aspirations
Alyssa Tapley, now 16, continues to be an inspirational figure in the advancement of this therapy. Her journey from a life-threatening diagnosis to active engagement in daily life serves as a profound testament to the potential of gene editing. Diagnosed in May 2021 after a prolonged period of symptoms that were initially attributed to viral illnesses, Alyssa’s leukemia proved resistant to standard chemotherapy and a bone marrow transplant. With palliative care being considered, the experimental BE-CAR7 therapy offered a last resort.
Reflecting on her decision to participate in the trial, Alyssa shared, "I chose to take part in the research as I felt that, even if it didn’t work for me, it could help others. Years later, we know it worked, and I’m doing really well. I’ve done all those things that you’re supposed to do when you’re a teenager." Her recovery has enabled her to pursue activities she once only dreamed of, including sailing, undertaking her Duke of Edinburgh Award, and attending school regularly. "I’m not taking anything for granted," she stated. "Next on my list is learning to drive, but my ultimate goal is to become a research scientist and be part of the next big discovery that can help people like me."
Funding and Infrastructure: Enabling Wider Access and Research
The development and ongoing clinical trials of BE-CAR7 have been supported by a consortium of funding bodies, including the Medical Research Council, Wellcome, and the National Institute for Health and Care Research (NIHR). GOSH also plays a pivotal role as the sponsor of the trial.
Significantly, the GOSH Charity has committed over £2 million to support treatment for an additional 10 T-ALL patients. This substantial investment aims to broaden access to the trial and aligns with the charity’s fundraising efforts for a new Children’s Cancer Centre, envisioned to accelerate cutting-edge research and enhance patient care. Patients eligible for NHS care who are interested in participating in the trial are encouraged to discuss this with their healthcare team.
The research infrastructure enabling these advancements is rooted in the UCL Great Ormond Street Institute of Child Health, where Professor Qasim leads a long-term research program. The team now operates from the Zayed Centre for Research into Rare Disease in Children, a state-of-the-art facility established through a generous £60 million gift in 2014 from Her Highness Sheikha Fatima bint Mubarak, in honor of her late husband, Sheikh Zayed bin Sultan Al Nahyan. This partnership between UCL and GOSH fosters collaboration and innovation in the field of rare disease research.
The researchers have also extended their gratitude to Anthony Nolan, a leading blood cancer charity, for their support in donor recruitment, as well as to the volunteer blood and stem cell donors and, most importantly, to the patients and families who have generously participated in this vital work.
Broader Implications and Future Outlook
The success of BE-CAR7 represents a significant stride in the fight against T-ALL, particularly for the approximately 20% of patients who do not respond to standard therapies. This gene-editing approach offers a tangible beacon of hope, potentially transforming outcomes for individuals with few other recourse. The development of "off-the-shelf" universal CAR T-cells also has profound implications for streamlining treatment delivery and potentially reducing costs associated with personalized cell therapies.
The implications extend beyond T-ALL. The successful application of base-editing in this context could pave the way for similar precision genome editing strategies to be applied to a wider range of hematological malignancies and other genetic diseases. The meticulous approach to safety, minimizing DNA cutting, addresses a key concern in the field of gene therapy, potentially accelerating the translation of research findings into widespread clinical practice. As the research progresses and more patients benefit from this innovative therapy, the landscape of pediatric and adult cancer treatment is poised for a profound and positive transformation.